QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
Top-Rated Stocks  
NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

$153.77
-1.80 (-1.16%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$153.14
▼
$156.27
50-Day Range
$149.93
▼
$160.47
52-Week Range
$125.36
▼
$169.98
Volume
342,283 shs
Average Volume
462,546 shs
Market Capitalization
$9.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$202.55

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
31.7% Upside
$202.55 Price Target
Short Interest
Healthy
4.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.78mentions of Jazz Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$2.82 M Sold Last Quarter
Proj. Earnings Growth
6.13%
From $15.18 to $16.11 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

99th out of 1,049 stocks

Pharmaceutical Preparations Industry

34th out of 514 stocks

See Top Rated MarketRank™ Stocks Here

JAZZ stock logo

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

January 29, 2023 | marketwatch.com
Medical Asparaginase Market Dynamics with Top Players, Gross Margin, Regional Demand, Plans and Demand Status Forecast to 2028
January 26, 2023 | finance.yahoo.com
FDA says it will not regulate CBD and calls on Congress to act
January 30, 2023 | Investing Trends (Ad)
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
January 25, 2023 | finance.yahoo.com
Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?
January 23, 2023 | marketwatch.com
Sulfanilamide Market To Show Incredible Growth And Forecast By 2028 Segment, Privacy Tools And Key Players Information
January 23, 2023 | marketwatch.com
Nonnarcotic Analgesics Market Size 2023 : Segment Overview, Company Profiles, Regional Analysis and Forecast 2029
January 23, 2023 | finanznachrichten.de
Lexaria Bioscience Corp.: Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
January 19, 2023 | msn.com
Jazz Pharma, Zymeworks post 84% overall survival for GIT cancer candidate
January 30, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 19, 2023 | finance.yahoo.com
Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals
January 19, 2023 | finance.yahoo.com
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
January 19, 2023 | finance.yahoo.com
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
January 18, 2023 | thestreet.com
Jazz Pharmaceuticals (JAZZ) Stock Falls in After-Hours Trading on Earnings Miss
January 16, 2023 | marketwatch.com
Clozapine Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook Report
January 14, 2023 | marketwatch.com
Lewy Body Dementia Treatment Market : Competitive Landscape and Analysis by Recent Trends 2023 to 2028
January 13, 2023 | benzinga.com
Psychedelic Drugs Market will worth USD 6703.3 million by 2030 : GreyViews
January 12, 2023 | marketwatch.com
Cytokine Storm Market 2023 : Advance Technology, Latest Trend and Future Expansion by 2028
January 11, 2023 | finance.yahoo.com
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
January 6, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Novan (NOVN)
January 6, 2023 | benzinga.com
Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?
January 3, 2023 | finanznachrichten.de
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023 | finance.yahoo.com
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022 | msn.com
Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial data
December 21, 2022 | finanznachrichten.de
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
December 20, 2022 | finance.yahoo.com
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
December 16, 2022 | marketwatch.com
Erwinase Market: Research Report on Some Key Drivers of Market Growth.
December 15, 2022 | finance.yahoo.com
Japan unit of Britain's Jazz Pharma starts phase III trial of cannabis drug
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings
11/09/2022
Today
1/30/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
CIK
1232524
Web
www.jazzpharma.com
Phone
(531) 634-7800
Fax
353-1634-7850
Employees
3,200
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$202.55
High Stock Price Forecast
$225.00
Low Stock Price Forecast
$187.00
Forecasted Upside/Downside
+31.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
10.13
P/E Growth
0.9
Net Income
$-329,670,000.00
Net Margins
-0.52%
Pretax Margin
-2.17%
Return on Equity
30.71%
Return on Assets
9.10%

Debt

Debt-to-Equity Ratio
2.07
Current Ratio
3.16
Quick Ratio
2.27

Sales & Book Value

Annual Sales
$3.09 billion
Price / Sales
3.13
Cash Flow
$22.68 per share
Price / Cash Flow
6.78
Book Value
$64.51 per share
Price / Book
2.38

Miscellaneous

Outstanding Shares
62,970,000
Free Float
60,195,000
Market Cap
$9.68 billion
Optionable
Optionable
Beta
0.74

Social Links


Key Executives

  • Mr. Bruce C. CozaddMr. Bruce C. Cozadd (Age 59)
    Co-Founder, Chairman & CEO
    Comp: $2.27M
  • Mr. Daniel N. Swisher Jr. (Age 60)
    Pres & COO
    Comp: $1.27M
  • Ms. Renee D. Gala (Age 51)
    Exec. VP & CFO
    Comp: $1.03M
  • Dr. Robert Iannone M.D. (Age 56)
    Exec. VP and Global Head of R&D
    Comp: $983.25k
  • Ms. Patricia Carr (Age 52)
    Sr. VP & Chief Accounting Officer
  • Dr. Finbar Larkin Ph.D. (Age 65)
    Sr. VP of Technical Operations
  • Ms. Andrea N. Flynn Ph.D.
    VP & Head of Investor Relations
  • Ms. Neena M. Patil J.D.Ms. Neena M. Patil J.D. (Age 48)
    Exec. VP & Chief Legal Officer
  • Dr. George Christopher Eliades Ph.D. (Age 52)
    Sr. VP of Corp. Devel. & Chief Transformation Officer
  • Ms. Heidi Manna (Age 51)
    Sr. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price forecast for 2023?

10 analysts have issued 12-month price targets for Jazz Pharmaceuticals' stock. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they anticipate the company's share price to reach $202.55 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2023?

Jazz Pharmaceuticals' stock was trading at $159.31 at the beginning of 2023. Since then, JAZZ stock has decreased by 3.1% and is now trading at $154.40.
View the best growth stocks for 2023 here.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our JAZZ earnings forecast.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings data on Wednesday, November, 9th. The specialty pharmaceutical company reported $4.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.35 by $0.18. The specialty pharmaceutical company had revenue of $940.65 million for the quarter, compared to analyst estimates of $939.88 million. Jazz Pharmaceuticals had a positive trailing twelve-month return on equity of 30.71% and a negative net margin of 0.52%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share guidance of $17.20-$17.85 for the period, compared to the consensus estimate of $17.41. The company issued revenue guidance of $3.60 billion-$3.70 billion, compared to the consensus revenue estimate of $3.65 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.28%), Allspring Global Investments Holdings LLC (0.20%), Nepsis Inc. (0.13%), Calamos Wealth Management LLC (0.08%) and Calamos Advisors LLC (0.07%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $154.40.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.72 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

The company employs 3,200 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 1/30/2023 by MarketBeat.com Staff